| Critètes d'éligibilité |
-
Patients must be enrolled on AALL08B1 or APEC14B1 (if available for ALL patients) prior to enrollment on AALL1131
-
White Blood Cell Count (WBC) Criteria
-
Age 1-9.99 years: WBC >= 50 000/uL
-
Age 10-30.99 years: Any WBC
-
Age 1-30.99 years: Any WBC with:
-
Testicular leukemia
-
CNS leukemia (CNS3)
-
Steroid pretreatment
-
Patients must have newly diagnosed B lymphoblastic leukemia (2008 World Health Organization [WHO] classification) (also termed B-precursor acute lymphoblastic leukemia); patients with Down syndrome are also eligible
-
Organ function requirements for patients with Ph-like ALL and a predicted TKI-sensitive mutation: patients identified as Ph-like with a TKI-sensitive kinase mutation must have assessment of organ function performed within 3 days of study entry onto the dasatinib arm of AALL1131
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
-
Age: Maximum Serum Creatinine (mg/dL)
-
1 to < 6 months: 0.4 (male) 0.4 (female)
-
6 months to < 1 year: 0.5 (male) 0.5 (female)
-
1 to < 2 years: 0.6 (male) 0.6 (female)
-
2 < 6 years: 0.8 (male) 0.8 (female)
-
6 to < 10 years: 1.0 (male) 1.0 (female)
-
10 to < 13 years: 1.2 (male) 1.2 (female)
-
13 to < 16 years: 1.5 (male) 1.4 (female)
-
> 16 years: 1.7 (male) 1.4 (female)
-
Direct bilirubin =< 3 x upper limit of normal (ULN) for age, and
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 10 x upper limit of normal (ULN) for age
-
Shortening fraction >= 27% by echocardiogram, or ejection fraction >= 50% by gated radionuclide study
-
Patients must have an electrocardiogram (EKG) fewer than 6 days prior to enrollment on the dasatinib arm; patients who have had cardiac assessments by echocardiogram or radionuclide scan at the beginning of induction do not need to have these repeated prior to study entry; correct QT interval (QTc) < 450 msec on baseline electrocardiogram as measured by the Frederica or Bazett formula
-
No major conduction abnormality (unless a cardiac pacemaker is present)
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% at sea level if there is clinical indication for determination
-
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine, phenytoin, primidone, phenobarbital) should be avoided
-
Eligibility criteria for the Longitudinal, Computerized Assessment of Neurocognitive Functioning study
-
Patients must be aged 6 to 13 years at time of B-ALL diagnosis, enrolled on AALL1131
-
Patients must be English-, French- or Spanish-speaking (languages in which the assessment is available)
-
Patients must have no known history of neurodevelopmental disorder prior to diagnosis of B-ALL (e.g., Down syndrome, Fragile X, William's Syndrome, mental retardation)
-
Patients must have no significant visual impairment that would prevent computer use and recognition of the visual test stimuli
-
Eligibility criteria for the National Cancer Institute (NCI) standard risk patients from AALL0932 enrolling on this study at the end of Induction
-
Effective March 19, 2018, patients enrolled on AALL0932, without Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL0932 or the HR B-ALL stratum of this study at the end of Induction:
-
Without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4+10), with day 8 peripheral blood (PB) minimal residual disease (MRD) >= 1% and day 29 BM MRD < 0.01%
-
With favorable cytogenetics (ETV6-RUNX1 or double trisomies 4+10), with any day 8 PB MRD and day 29 bone marrow (BM) MRD >= 0.01%
-
Both NCI standard risk (SR) and HR patients without Down syndrome and with testicular disease at diagnosis, who do not meet other VHR criteria
-
Effective Amendment 6, patients enrolled on AALL0932, without Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL0932 or the VHR stratum of AALL1131:
-
Intrachromosomal amplification of chromosome 21 (iAMP21)
-
Mixed-lineage leukemia (MLL) rearrangement
-
Hypodiploidy (n < 44 chromosomes and/or a deoxyribonucleic acid [DNA] index < 0.81)
-
Induction failure (M3 BM at day 29)
-
Without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4+10), with day 29 BM MRD >= 0.01%
-
Patients enrolled on AALL0932, with Down syndrome, meeting the following criteria will NOT be eligible to continue on AALL0932 but WILL BE eligible to enroll on the DS HR B-ALL stratum of this study at the end of Induction:
-
Day 29 MRD >= 0.01%
-
MLL rearrangement
-
Hypodiploidy (n < 45 chromosomes and/or DNA index < 0.81)
-
DS HR B-ALL patients initially enrolled on AALL0932 or this study who have Induction failure (M3 BM day 29) or Philadelphia chromosome (BCR-ABL1) will not be eligible for post-Induction therapy on either trial (AALL0932 or AALL1131)
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and NCI requirements for human studies must be met
|
HOPITAL DE MONTREAL POUR ENFANTS
Actif en recrutement
Groupe d'étude en oncologie du Québec